30 May 2023

Media Contact

Jessica Byrnes

Coordinator, Marketing & Communications

Society of Interventional Oncology Announces Medical College of Wisconsin Cancer Center Now Enrolling in ACCLAIM Study

Washington, DC (30 May 2023) – The Society of Interventional Oncology (SIO) proudly announces Medical College of Wisconsin Cancer Center as the next US site approved and enrolling in the society’s primary clinical trial, “Ablation with Confirmation of Colorectal Liver Metastases (ACCLAIM) Prospective Trial for Microwave Ablation as a Local Cure.” The Medical College of Wisconsin Cancer Center site investigators are Amanda Smolock, MD, PhD and William Rilling, MD, FSIR.

Dr. Constantinos T. Sofocleous is the Global Principal Investigator for the study. “We are excited and pleased to share our fourth US site, Medical College of Wisconsin Cancer Center is now activated and has begun patient enrollment in the ACCLAIM Trial,” said Sofocleous. “We look forward to sharing other sites in the US and Europe as they are approved for enrollment to begin.”

This multimillion-dollar trial is funded collectively through grants from Boston Scientific CorporationNeuWave Medical, Inc. (part of Ethicon, Inc.), and Varian, a Siemens Healthineers Company.


About the Society of Interventional Oncology (SIO) 

SIO serves as the only membership-based organization dedicated to the emerging field of interventional oncology (IO), working to establish, nurture, and support IO as the fourth pillar of cancer therapy alongside medical, surgical, and radiation oncology worldwide. IO therapies, such as embolization and tumor ablation, combine the expertise of oncology and radiology and use imaging technology to diagnose and treat localized cancers in ways that are precisely targeted and minimally or non-invasive. For more information, please visit

About the ACCLAIM (Ablation with Confirmation of Colorectal Liver Metastases) Trial

In this multi-center, international trial, SIO proposes to establish microwave ablation (MWA) as the preferred treatment option for selected colorectal liver metastases that can be ablated with sufficient margins. The study is the first global, prospective trial to use an objective and reproducible technical outcome in its study design, which SIO believes will drive important changes to future treatment guidelines. The study will incorporate software to assess the ablation zone and margins and determine if achieving complete margins during an ablation equates to procedural success, where the primary outcome is local disease progression at two-years post-ablation. For more information, please visit,

Twitter  Linkedin  Facebook